Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone919-237-5300
Debt
Current Ratio7.05
Quick Ratio6.89
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book11.60
Profitability
Net Income$-145,100,000.00
Net MarginsN/A
Return on Assets-65.99%
Miscellaneous
Employees160
OptionableOptionable
Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions
What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
How were Aerie Pharmaceuticals' earnings last quarter?
Aerie Pharmaceuticals Inc (NASDAQ:AERI) issued its quarterly earnings data on Tuesday, November, 6th. The company reported ($1.73) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.33) by $0.40. The company had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.63 million. View Aerie Pharmaceuticals' Earnings History.
When is Aerie Pharmaceuticals' next earnings date?
What price target have analysts set for AERI?
11 equities research analysts have issued 1 year target prices for Aerie Pharmaceuticals' stock. Their predictions range from $64.00 to $105.00. On average, they anticipate Aerie Pharmaceuticals' share price to reach $79.0909 in the next year. This suggests a possible upside of 86.3% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.
What is the consensus analysts' recommendation for Aerie Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.
What are Wall Street analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "While the glaucoma market holds potential, Aerie faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Shares have underperformed the industry in the past twelve months. The FDA approval of Aerie’s lead drug, Rhopressa is a significant boost for the company. Aerie is also evaluating Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan (latanoprost). The PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the Rocklatan NDA is set for Mar 14, 2019. Loss estimates have widened ahead of the Q4 earnings and the company has a negative earnings surprise in the recent quarters." (1/15/2019)
- 2. Mizuho analysts commented, "We note that one or two weeks of data can have a meaningful impact on our total 2018 projections and we used what we believe are conservative assumptions. We believe there could be upside to our current estimate and we believe the risk of Aerie not delivering on its 2018 sales guidance of $20-30 mil is low." (11/27/2018)
- 3. Cantor Fitzgerald analysts commented, "We rate Aerie Pharmaceuticals Overweight. AERI commercializes and develops once- daily eye drops Rhopressa and Roclatan, respectively, for glaucoma. Rhopressa is the first novel drug in a market that has not seen innovation in 20 years. Valuation Summary We value Aerie based on the NPV of the cash flows associated with its glaucoma drug candidates. Our price target is $86/share." (10/2/2018)
- 4. Canaccord Genuity analysts commented, "We hosted Aerie CFO a fireside chat this afternoon at the Canaccord Genuity Growth Conference. Aerie is an ophthalmology company that recently launched Rhopressa, the first new class of glaucoma drugs in over twenty years. In addition to Rhopressa, Aerie plans to commercialize Roclatan, a combination of Rhopressa and latanoprost, the leading glaucoma therapy in the US market. Beyond glaucoma, Aerie is exploring the use of ROCK inhibitors in back-of-the-eye conditions like wet AMD and could explore opportunities to utilize ROCK inhibitors outside of ophthalmology. Rhopressa tracking well with strong user feedback. Launched earlier this year, Rhopressa is already gaining traction with ophthalmologists and patients, and Aerie is pleased with the current uptake trajectory." (8/10/2018)
Has Aerie Pharmaceuticals been receiving favorable news coverage?
News headlines about AERI stock have been trending positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aerie Pharmaceuticals earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the near future.
Who are some of Aerie Pharmaceuticals' key competitors?
Some companies that are related to Aerie Pharmaceuticals include bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Spark Therapeutics (ONCE) and Autolus Therapeutics (AUTL).
Who are Aerie Pharmaceuticals' key executives?
Aerie Pharmaceuticals' management team includes the folowing people:
- Dr. Vicente J. Anido Jr., CEO & Chairman (Age 65)
- Mr. Thomas A. Mitro, Pres & COO (Age 60)
- Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 57)
- Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 60)
- Ms. Jessica Crespo CPA, Director of Accounting
How do I buy shares of Aerie Pharmaceuticals?
Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerie Pharmaceuticals' stock price today?
One share of AERI stock can currently be purchased for approximately $42.45.
How big of a company is Aerie Pharmaceuticals?
Aerie Pharmaceuticals has a market capitalization of $1.92 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.
What is Aerie Pharmaceuticals' official website?
How can I contact Aerie Pharmaceuticals?
Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]
MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
